Media Coverage
Chris Dokomajilar from DealForma joins this podcast by RX for Biotech to explore the investment trends in advanced therapies and AI within biopharma, using insights from DealForma’s detailed life science database.
John Carroll talks about the Q4 2023 biotech sector in a report that reveals a significant uptick in mergers and acquisitions, highlighting a change towards growth amid valuation and economic headwinds.
J.P. Morgan utilized Dealforma’s comprehensive data to compile their 2023 Annual Biopharma Licensing and Venture Report, highlighting key trends in funding, mergers, acquisitions, and more within the biopharma sector.
Utilizing DealForma’s data, Nature’s article showcases selected deals focusing on cardiovascular diseases, CNS disorders, and the oligonucleotide therapies driving these advancements.
In January 2024, the rare disease therapeutics sector experienced a funding surge to nearly $3 billion, indicating a strong start to the year.
